Diagnosis and Management of Hypertension
Hypertension should be diagnosed after two or more elevated readings obtained on at least two visits over 1-several weeks, with blood pressure classified as normal (<120/80 mmHg), elevated (120-129/<80 mmHg), stage 1 hypertension (130-139/80-89 mmHg), or stage 2 hypertension (≥140/≥90 mmHg). 1
Diagnostic Criteria
Blood Pressure Classification
- Normal: <120/80 mmHg
- Elevated: 120-129 mmHg systolic and <80 mmHg diastolic
- Stage 1 Hypertension: 130-139 mmHg systolic or 80-89 mmHg diastolic
- Stage 2 Hypertension: ≥140 mmHg systolic or ≥90 mmHg diastolic 1
Proper Measurement Technique
- Use a properly calibrated and validated device
- Ensure proper patient preparation (seated, back supported, arm at heart level)
- Take at least 2-3 readings with 1-2 minutes between them
- Confirm diagnosis with out-of-office measurements (home or ambulatory monitoring) to avoid white coat hypertension 1
Diagnostic Confirmation
- Diagnosis requires elevated readings on at least two separate visits
- Single-visit measurements can overestimate prevalence by approximately 12.6% 2
- Home BP threshold corresponding to clinic BP of 130/80 mmHg is approximately 130/80 mmHg across different ethnic groups 3
Treatment Options
Lifestyle Modifications (First-Line for All Patients)
- Diet: Mediterranean or DASH diet recommended to reduce BP and cardiovascular disease (CVD) risk 4
- Physical Activity: Regular aerobic exercise (150-300 minutes/week) complemented with resistance training 2-3 times/week 4
- Weight Management: Aim for BMI 20-25 kg/m² and waist circumference <94 cm (men) and <80 cm (women) 4
- Sodium Reduction: Limit sodium intake and increase potassium intake 5
- Alcohol Limitation: Consume less than 100g/week of pure alcohol, preferably avoid completely 4
- Smoking Cessation: Stop tobacco use and refer to cessation programs 4
- Sugar Restriction: Limit free sugar to maximum 10% of energy intake, avoid sugar-sweetened beverages 4
Pharmacological Treatment
When to Initiate Medication
- Elevated BP with low/medium CVD risk: Start with lifestyle modifications 4
- Elevated BP with high CVD risk: After 3 months of lifestyle intervention, start medication if confirmed BP ≥130/80 mmHg 4
- Confirmed BP ≥140/90 mmHg: Promptly initiate both lifestyle measures and pharmacological treatment regardless of CVD risk 4
First-Line Medications
- Recommended initial therapy: Combination treatment for most patients with confirmed hypertension (BP ≥140/90 mmHg) 4, 5
- Preferred combinations:
Treatment Escalation
- If BP not controlled with two-drug combination, increase to three-drug combination (RAS blocker + CCB + thiazide/thiazide-like diuretic) 4
- Avoid combining two RAS blockers (ACE inhibitor and ARB) 4
- Beta-blockers recommended when specific indications exist (angina, post-MI, heart failure) 4
Blood Pressure Targets
- Target systolic BP of 120-129 mmHg for most adults if well tolerated 4
- If target cannot be achieved due to poor tolerance, aim for "as low as reasonably achievable" (ALARA principle) 4
Treatment Monitoring and Follow-up
- Measure BP at every routine clinical visit or at least every 6 months 1
- Monitor until target BP is achieved (within 3 months) 1
- Maintain BP-lowering treatment lifelong if well tolerated 4
- Take medications at the most convenient time of day to improve adherence 4
Common Pitfalls and Caveats
- Diagnostic errors: Relying on single-visit measurements can lead to overdiagnosis 2
- White coat hypertension: Confirm office readings with home or ambulatory monitoring 1
- Medication adherence: Fixed-dose combinations improve adherence compared to multiple pills 4
- Elderly patients: Consider frailty and orthostatic hypotension when initiating therapy 4
- Therapeutic inertia: Failure to intensify treatment when BP goals are not met 1
Hypertension is the leading risk factor for cardiovascular disease globally, affecting approximately one-third of adults 1. Proper diagnosis and management significantly reduce the risk of coronary heart disease, heart failure, stroke, and all-cause mortality 1, 5.